🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05369689
Starting soon Observational

Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics

NCT05369689 · tracked via the Priya Life Science China tracker
Sponsor
Zhuang Hongqing
Phase
Observational
Started
2022-06-01
Last updated
2022-05-11

Condition(s) studied

Stereotactic RadiosurgerySpinal TumorRadiomicsPrognosis

Investigational drug(s) / intervention(s)

No interventions

No interventions: As this is a prognosis evaluation study, there are no interventions.

Study summary

This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: A diagnosis of spinal tumors for which SBRT is appropriate Karnofsky Performance Status \>60 Life expectancy of at least 3 months No contraindication to undergoing MR imaging Age \>18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery Exclusion Criteria: Subjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and/or rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed. Subjects with spinal cord compression; minimally invasive "separation" surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist. Beijing Beijing Municipality

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05369689 on ClinicalTrials.gov ↗ ← All trials in China